AnaptysBio Inc reports results for the quarter ended in December - Earnings Summary

AnaptysBio

11/03/2024 21:28

* AnaptysBio Inc  ANAB.OQ  reported a quarterly adjusted
loss of
$1.59​​ per share for the quarter ended in December, lower than
the same quarter last year, when the company reported EPS of -93
cents.  The mean expectation of nine analysts for the quarter
was for a loss of $1.60 per share. Wall Street expected
results to range from $-2.08 to $-1.07 per share.
    * Revenue rose 32.3% to $9.01 million from a year ago;
analysts
expected $2.23 million. 
    * AnaptysBio Inc's reported EPS for the quarter was a loss
of
$1.59​.
    * The company reported a quarterly loss of $42.21 million.
    * AnaptysBio Inc shares had risen by 15.8% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for AnaptysBio Inc is
$37.00 
This summary was machine generated from LSEG data March 11 at
09:27 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.60          -1.59          Beat
 Sep. 30 2023      -1.79          -1.41          Beat
 Jun. 30 2023      -1.70          -1.50          Beat
 Mar. 31 2023      -1.05          -1.58          Missed